Résultats de la recherche - Ada Azaryan
- Résultat(s) 1 - 3 résultats de 3
-
1
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study par Peter Schäfer, Alan Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Publié 2019Artigo -
2
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study par Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda, David Cunningham, Roberto S Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg
Publié 2021Artigo -
3
Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia par Jennifer R. Brown, Wael A. Harb, B. T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, TP Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Y. Li, Daniel W. Pierce, Elizabeth D. Barnett, Joseph E. Marine, Michele Miranda, Ada Azaryan, Xu Y, Pilar Nava-Parada, Jay Mei, Thomas J. Kipps
Publié 2016Carta
Outils de recherche:
Sujets similaires
Internal medicine
Medicine
Biology
Lymphoma
Oncology
Receptor
Tyrosine kinase
Adverse effect
Antibody
Astrobiology
Bruton's tyrosine kinase
CD23
CD34
CD38
CXCL13
Cancer research
Chemistry
Chemokine
Chemokine receptor
Chronic lymphocytic leukemia
Clinical trial
Cytokine
Gastroenterology
Genetics
Ibrutinib
Immune system
Immunoglobulin E
Immunology
Inflammation
Leukemia